Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI9253 + Durvalumab in Advanced Solid Tumors
NCT04613492Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label trial of MEDI9253 in solid tumor (6 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) and Number of Participants With Dose-limiting Toxicities at Day 28. Started Dec 2020; status: terminated.
02
Drugs
MEDI9253
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04613492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613492.